Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab followed by argon laser for macular edema due to branch retinal vein occlusion
ACTRN12617001436369Phase 4Completed
- Sponsor
- Hospital Oftalmológico de Sorocaba
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in branch retinal vein occlusion (BRVO) and macular edema, sponsored by Hospital Oftalmológico de Sorocaba. Primary endpoint: Proportion of participants with recurrence of macular edema following maximal visual acuity stabilisation. Started May 2016; status: completed.
02
Drugs
bevacizumab
03
Conditions
branch retinal vein occlusion (BRVO)macular edema
Beyond the preview
Go deeper on ACTRN12617001436369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001436369.